Annual Corporate Profiles 2014-2015 by McMahon Group

27th Annual

2014-2015

Available online @ AnesthesiologyNews.com

Anesthesia Business Consultants 18 Grifols 19 B. Braun Medical Inc. 20 Dräger 22 Edwards Lifesciences 24 MAQUET Medical Systems USA 26 Masimo 28 Mindray 30 Pacira Pharmaceuticals, Inc. 32 Teleﬂex 33 Par Sterile Products, LLC 34 Spacelabs Healthcare 36 TeamHealth Anesthesia 38 McMahon Publishing 40

2014-2015

th Corporate

ANNUAL

Profiles

ANESTHESIA S S BUSINESS US SS CONSULTANTS CO SU S

nesthesia Business Consultants, LLC (ABC) is the largest billing and practice management company dedicated to the complex and intricate specialty of anesthesia and pain management. It is both an Anesthesia Quality Institute Preferred Vendor and a Gold Affiliate with the Medical Group Management Association. Tony Mira, ABC’s founder, president and CEO, has maintained a concentration on providing services exclusively to anesthesia and pain management professionals since the company’s inception more than 30 years ago. ABC distinguishes itself by providing optimal business tools to strengthen business processes and enhance cash flow—all while keeping pace with constant changes in the health care environment. ABC prides itself on the longevity of its client relationships and its ability to customize services to the unique requirements of each practice. ABC offers its clients innovative billing and reimbursement services, as well as valuable practice management tools and solutions that allow them to realize their own particular strategic visions and business plans.

resulting in faster claims resolution and higher levels of reimbursement. Extensive management reporting options allow both management and client to monitor subtle changes in payer mix and reimbursement patterns. Services include: • Front-end edit and claim-scrubber technology • Patient deductible strategies and solutions • Claim underpayment monitoring and reporting

Management Support Services No one company is more qualified to furnish critical management information and proactively advise practice decision makers. ABC stands alone in its ability to provide a full range of management support services: • Strategic management • Practice management • Practice consulting • Financial services • Quality management (PQRS) • Human resources consulting • Contracting services • Compliance and HIPAA • Education and training

AT A GLANCE ADDRESS 255 West Michigan Ave. Jackson, MI 49201 (800) 242-1131

WEBSITES www.anesthesiallc.com www.communiquenews.com

SOCIAL MEDIA http://www.anesthesiallc.com/ easyblog/latest http://twitter.com/AnesthesiaLLC https://www.facebook.com/ anesthesiallc http://www.linkedin.com/company/ anesthesia-business-consultants https://plus.google.com/10046113 4039781832016#100461134039 781832016/posts

The ABC Management Advantage ABC distinguishes itself through its focus, operational approach and management structure: • Unlike many competitors who continually redefine their market focus, ABC has remained true to its core market of anesthesiologists, certified registered nurse anesthetists and pain management specialists, enhancing the credibility of its insight and advice. • ABC believes its relationship with its clients is a true partnership—a partnership in which ABC not only helps improve the billing process, but also helps the group operate more efficiently in the operating room, and more proactively in its relationship with the hospital. • ABC’s centralized approach allows effective management and oversight, ensuring consistent results. • Managing a business based on the input and expectations of shareholders does not always result in the most appropriate business decision making. Because ABC is privately held, it has much greater flexibility in setting its agenda, managing the business and being responsive to its clients’ needs.

The ABC Service Advantage ABC offers a full range of services designed to meet its clients’ needs, from a specific area of service to an allencompassing solution partner.

Billing and Reimbursement Services Because all processing is centralized, ABC maintains its high standards for quality control and efficiency,

Tony Mira, president and CEO

Anesthesiology News • August 2014

The ABC Technology Advantage To ensure flexibility with its clients and their varying level of needs, ABC has carefully crafted a portfolio of products to meet client needs during the entire perioperative process. The most advanced, secure and reliable software designed especially for anesthesia billing and practice management, F1RSTAnesthesia T ™ converts clinical information into claims for reimbursement. This powerful tool supports electronic claims editing to ensure consistently high billing acceptance rates and minimizes manual intervention in payment posting through direct remittance processing. Providers also are able to receive real-time or historical information through F1RSTAnesT thesia’s web-based technology or advanced data warehousing/data-mining technology. OneSourceAnesthesia is a powerhouse platform that offers an à la carte approach to the complete perioperative process—clients choose the features they need now, and have the peace of mind that comes from knowing OneSourceAnesthesia e is adaptable and that they can add increasing functionality as their needs grow and change. The OneSourceAnesthesia e platform offers: • Patient portal • Anesthesia Information Management Systems (AIMS) • Postoperative quality • Call scheduling • Patient satisfaction • Patient monitoring • Meaningful use The primary hardware tool required for ABC’s solution is an Apple iPad. The OneSourceAnesthesia solution requires no interaction with the hospital or surgery center’s servers to host the software. These elements, when combined with the intuitive user experience of OneSourceAnesthesia e , offer an unparalleled platform to

SERVICES Full-service billing and practice management firm dedicated exclusively to anesthesiologists and pain management physicians.

EMPLOYEES 850+

streamline and automatically incorporate best practices and clinical protocols to any practice. • F1RSTUse is the first full-service EMR management platform built exclusively for anesthesiologists and pain management specialists to satisfy stages 1 and 2 of meaningful use that are required to earn the Medicare or Medicaid EHR incentive payment. • F1RSTAnalytics T provides Insight at Your Fingertips. We all know that data helps us make better, more educated decisions. But collecting large amounts of data is ineffective without the proper tools to display those insights. Without understanding the context of a specific metric, it can be easily misunderstood and misrepresented. Physicians and managers alike require a smooth transition from the clinical, administrative and operational data sets to better understand the true messages that the data are trying to tell. Make the Data Work for You. F1RSTAnalytics T is the ultimate in technical sophistication. It offers data prowess, providing the data to aid in operating your anesthesia practice as an effective clinical organization and successful business. The information you need, provided in a way you can use it.

This corporate profile was reviewed and approved by Anesthesia Business Consultants.

2014-2015

th Corporate

ANNUAL

Profiles

G O S GRIFOLS AT A GLANCE

rifols is a global health care company with a 70-year legacy of improving people’s health and well-being through the development of life saving plasma medicines, diagnostics systems and hospital pharmacy products. Caring for people is its commitment that remains unchanged since the company started. Grifols is one of the leading companies in the world in the production of life saving plasma therapies, with a business model based on vertical integration, enabling it to control the entire production cycle, starting with the collection of raw material in the form of plasma through an extensive network of donor centers in the United States, and ending with the finished product.

A Legacy of Innovation At Grifols, a history of innovation defines our modern-day approach to medicine. More than 70 years ago, a Spanish hematologist named Dr. Jose Antonio Grifols Roig pursued a line of research that would set the stage for contemporary use of human plasma to treat disease. Together with his sons, he founded Laboratorios Grifols in 1940. Among their pioneering achievements, they obtained a patent in Spain for the process of plasma lyophilization, or freeze-drying of human plasma, along with the devices needed to inject plasma into patients who required its therapeutic properties. Shortly after, in 1951, Dr. Jose Antonio Grifols Lucas published the first large-scale clinical data describing the plasmapheresis technique of extracting plasma from donors while returning their red blood cells. Combined with the work of Edwin Cohn, Grifols paved the way for the birth of the plasma fractionation industry as we know it today.

Expanding To Meet the Demand From these auspicious beginnings, Grifols has evolved into an industry leader in the collection, manufacture and marketing of plasma-derived therapies. Through recent acquisitions, Grifols is now the third largest global producer of plasma-derived medicines. Grifols operates the world’s largest plasma collection platform, with 150 source plasma donation centers across the United States. Grifols has a current capacity of plasma protein fractionation of more than 9 million liters of plasma per

ADDRESS Grifols 2410 Lillyvale Ave. Los Angeles, CA 90032 (888) GRIFOLS (474-3657) www.grifols.com

DIVISIONS Bioscience: Specializes in the research, development, production and commercialization of high-quality plasma therapies. Edwin J. Cohn & Jose Antonio Grifols at the 4th International Congress of Blood Transfusion, Lisbon, 1951.

year. To accommodate the growing global demand for plasma-derived medicines, Grifols is significantly expanding its three manufacturing sites in Clayton, N.C., Los Angeles and Barcelona, Spain—the company’s global headquarters. The expansions include a new, 185,000-square-foot fractionation facility in Clayton and a new facility in Los Angeles dedicated to the production of immune globulin therapies. The new manufacturing facilities will increase the company’s capacity to fractionate plasma to 12 million liters by 2015. In addition, last year, Grifols opened a new, state-ofthe-art plasma testing laboratory in San Marcos, Texas, where every plasma donation undergoes rigorous scientific analysis before being approved for use in manufacturing. The 72,000-square-foot facility houses the latest technology for conducting sophisticated viral testing, including transcription-mediated amplification to rapidly detect minute levels of viral material in plasma samples. The San Marcos laboratory, together with an existing plasma testing laboratory in Austin, will analyze millions of plasma samples annually. Grifols is firmly committed to giving patients and health care providers broad access to our products. As Grifols grows, it continues to pursue its mission of improving the health and well-being of people around the world.

Hospital: Specializes in operational solutions for compounding areas in pharmacy. Diagnostic: Provides a comprehensive range of transfusion medicine, hemostasis, and immunoassay solutions for clinical laboratories, blood banks and transfusion centers.

PRODUCTS Albumin (Human), marketed as Albutein® 5%, Albutein® 25% and Plasbumin® _ 5 and Plasbumin® _ 25 Alpha1-Proteinase Inhibitor (Human), marketed as Prolastin®-C Antihemophilic Factor/von Willebrand Factor Complex (Human), marketed as Alphanate® Antithrombin III (Human), marketed as Thrombate III® BloodChip® for blood genotyping, Coagulation Factor IX (Human), marketed as AlphaNine® SD DG Gel® cards for blood typing Erytra® and Wadiana® automated blood typing instruments Factor IX Complex, marketed as Profilnine® SD Hyperimmune Globulin Therapy Products: • Rabies Immune Globulin (Human) • Tetanus Immune Globulin (Human) • Rho (D) Immune Globulin (Human) • Hepatitis B Immune Globulin (Human) Immune Globulin Intravenous (Human) or IVIG Immune Globulin Injection (Human) Gri-fill® System 3.0 for compounding sterile preparations Misterium® modular clean room solution Grifols-SencorpWhite inventory management system solutions Phocus® Rx: remote pharmacist validation system for compounding IV preparations Procleix NAT solutions for blood testing Grifols Triturus® Fully Automated EIA Analyzer Interlab G26 Clinical Agarose Gel Electrophoresis Systems A focused selection of reagents for infectious serology, autoimmunity, oncology and celiac disease

IVIG manufacturing plant in Barcelona, Spain, designed by Grifols Engineering.

This corporate profile was reviewed and approved by Grifols.

Anesthesiology News • August 2014

1919

2014-2015

th Corporate

ANNUAL

Profiles

B. BRAUN U MEDICAL C INC. C

Braun Medical Inc. (B.Braun), a leader in infusion therapy and pain management, develops, manufactures and markets innovative medical products and services to the health care industry. B.Braun is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. Guided by its “Sharing Expertise®” philosophy, B.Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. The B.Braun group of companies in the United States includes B.Braun, B.Braun Interventional Systems, Aesculap® and CAPS®. B.Braun’s U.S. headquarters is located in Bethlehem, Pa. The B.Braun Group employs more than 50,000 employees in more than 60 countries worldwide. To learn more about B.Braun, visit www. BBraunUSA.com.

B.Braun Pain Management B.Braun is the global and U.S. market leader in regional anesthesia (RA). Our mission is simple—to help our customers reduce costly adverse outcomes, for patients and the facility itself, as a result of the overuse or sole dependency on opioids and gas anesthesia. B.Braun is here to advocate for, and educate on, the benefits of RA; and provide products and services to help improve patient outcomes, along with your bottom line. Our goal is to continue to be the customer’s first choice for safe and effective infusion therapy by investing in education, innovation and quality improvement initiatives.

Here are four ways B.Braun can help today: 1. Increase awareness for Regional Anesthesia. Are you trying to understand the benefits of an RA program, or sell the advantages to your facility, surgeons or nursing team? www.RAAdvantages.com can help by highlighting the cost of adverse events and the associated advantages of RA. Your choices matter—know how these choices impact your patient’s and facility’s bottom line.

Anesthesiology News • August 2014

2. Learn how to start or expand a program for continuous peripheral nerve blocks. Are you aware of the benefits of RA and seeking to increase use, but need assistance with the process? B.Braun has a team of nationally recognized and published anesthesia and nurse consultants, and centers of excellence that can tailor learning specific to your anesthesia groups’ needs. Be the change—advocate and lead your growth and expansion. 3. Standardize to B.Braun. Are you trying to consolidate your suppliers to help reduce costs, complexity and standardize clinical practice across multiple sites? B.Braun has one of the widest portfolios in the industry to help provide choice. At the same time, we have the knowledge and processes to help guide standardization. Treat every patient the same—why should they expect to be treated differently based solely on where they seek care within your health care system? 4. Innovation through consultation. Working with our network of key opinion leaders, watching you work and listening to your concerns—that’s how we’re developing the products and services you will need in the future to be competitive and deliver a superior level of quality care. Recently, B.Braun launched the Contiplex® C, www.contiplexc.com, a revolutionary catheter-over-needle system to help reduce placement time and leakage; as well as Contiplex Echo, the first echogenic needle and catheter system, to help facilitate quicker and easier visualization under ultrasound. Interested in joining our key opinion leader network or providing feedback? Email KOL.us@bbraunUSA.com along with your area of expertise and suggestions.

More on our product portfolio: Epidural. B.Braun’s market-leading Perifix® epidural line is enhanced by the Perifix FX Springwound

AT A GLANCE ADDRESS 824 Twelfth Ave. Bethlehem, PA 18018 (800) 227-2862 www.bbraunusa.com

PRODUCTS Pain control products; disposable post-op pain pumps; IV solutions in latex-, PVCand DEHP-free bags; needle-free systems; electronic pump delivery systems

CEO, CHAIRMAN OF THE BOARD Caroll H. Neubauer

Epidural Catheter. Designed to reduce paresthesia and vessel puncture rates, the FX is available in open-tip uniport and closed-tip multiport versions. For more information on the Perifix FX, please visit www.perifixfx.bbraunusa.com/AN. Spinal. B.Braun’s Pencan® Pencil Point spinal needle is designed for high flow rates for rapid detection of cerebrospinal fluid. B.Braun’s complete RA portfolio also features a patented combined spinal epidural product line. The Espocan® Docking System enables anesthesia providers to lock the position of the spinal needle during combined-technique procedures. The small, unobtrusive docking system sleeve helps inhibit forward and backward movements of the spinal needle while still permitting needle rotation. Peripheral nerve block. With ultrasound practitioners in mind, Ultraline is designed to enhance needle visibility at steep angles where visualization may be more challenging. Ultraline technology is featured in three configurations: Stimuplex® Ultra, a stimulating single-shot needle; Ultraplex, a nonstimulating single-shot needle; and Contiplex Tuohy Ultra, a stimulating needle for placing catheters under ultrasound. For more information on Ultraline needle markings and applications, please visit www.stimuplexultra.com.

This corporate profile was reviewed and approved by B. Braun Medical Inc.

Kareem M Eltaki, MD Anesthesiologist

Ramapo Anesthesia Group Dr. Kareem Eltaki’s number one priority is the patient. Comfortable patients lead to quicker recoveries. “Regional Anesthesia is getting patients quickly and more comfortably out of the hospital and reducing the narcotics administered for post-op pain management.” “I can tell you, the orthopedic procedures we’re doing the blocks on, we’re not giving opioids. In most cases when I do a block, I won’t even have a narcotic on me. With Regional Anesthesia, we’ve seen the amount patients need post-op and in recovery is almost none, especially in the best case scenarios”.

Profitability RA AdvantagePr

“Our patients matter most. By minimizing post-op pain and decreasing side effects, we’re improving the patient experience significantly.”

RAadvantages.com

Relationships

where advocates for the best in patient care and controlling healthcare costs come together.

Learn more at RAadvantages.com 14-43 321B_AN_7/14_RTS3

2014-2015

th Corporate

ANNUAL

Profiles

DRÄGER G Technology for Life®

räger develops innovative medical solutions trusted by people the world over when lives are on the line. “Technology for Life” means more than merely guaranteeing technical excellence. It means assuming responsibility for the lives of those who use our products and depend on them. Technology for Life is both our guiding principle and the central challenge that we draw on for inspiration and motivation. “We do everything we do with passion—and we do it for life.” —Stefan Dräger, Executive Board chairman

125 Years of Heartfelt Dedication Dräger is a family enterprise, publicly traded in Germany and family co-owned, managed and led by the fifth generation of the company’s founders. In 2014, we are celebrating our 125th anniversary and we are convinced: This is the right time to say “thank you.” Thanks to our customers, who join us in our commitment to life. Thanks to our employees, who develop technology that puts life first and find innovative solutions for our customers. And thanks to our business partners, who help us stay connected and invest in our joint future.

AT A GLANCE Global Leader in Medical Technology As a leader in medical and safety technology, Dräger has approximately 12,500 employees worldwide. The company is present in more than 190 countries to effectively serve customers around the globe. The expertise of our management and employees is crucial to the growing globalization of our company. Our employees are characterized by their customer focus, entrepreneurial attitude, flexibility and global orientation.

Integrated anesthesia solutions that simplify operation so you can focus on your patients Dräger anesthesia workstations can include a number of tightly integrated components, including anesthesia machines, patient monitors, clinical IT applications and volatile gas analysis technology. The seamless integration enables the electronic, automated capture of anesthesia data that help users focus on patients—not paperwork.

Integrated monitoring solutions that make it easier to get the information you need It starts with an open architecture design and an ability to host multiple applications simultaneously. The widescreen format of our Infinity® Omega monitoring solutions puts more data at your fingertips at one time. As an electronic version of the traditional patient folder, they can save you time, facilitate decision making and help reduce the potential for medical errors. Plus, uninterrupted patient monitoring from pre-op to the postanesthesia care unit ensures the most complete patient picture possible.

Platform consistency that protects your investment and your patients Dräger’s consistency of platforms makes training more transparent, helping to minimize training costs and reduce errors. The use of a consistent user interface across Dräger anesthesia product lines can significantly reduce

CORPORATE HEADQUARTERS Drägerwerk AG & Co. KGaA Moislinger Allee 53-55 23558 Lübeck, Germany +49-451-882-0 info@draeger.com

NORTH AMERICAN HEADQUARTERS Draeger Medical, Inc. 3135 Quarry Rd. Telford, PA 18969 (800) 4-DRAGER (437-2437) info.usa@draeger.com www.draeger.com

PRODUCTS Anesthesia machines, patient monitors, anesthesia information management system, enterprise monitoring solutions, information technologies, ventilation therapy, warming therapy, architectural systems, accessories, surgical lighting, DrägerService®, education and training

EMPLOYEES Approximately 12,500 worldwide

PRESIDENT AND CEO Stefan Dräger

the time needed to learn all the platforms required to support various care settings, ranging from the operating room to magnetic resonance imaging and mobile environments. More importantly, it enables a familiarity that allows you to react intuitively, confidently and efficiently. To learn more about Dräger anesthesia workstations, please contact your local anesthesia sales representative or visit us online at www.draeger.com.

The Infinity Omega-S brings together patient data from diverse sources—such as vital signs, lab data, DICOM images (x-ray, MRI, CT, US) and access to the patient’s electronic medical record. The Infinity Omega-S solution is part of Dräger’s comprehensive anesthesia workstation.

Anesthesiology News • August 2014

This corporate profile was reviewed and approved by Dräger.

Premium performance at and

low

minimal ﬂows

Deliver low and minimal flow anesthesia with workstations designed for it For more than a century, clinicians have trusted Dräger’s innovative anesthesia solutions to improve the practice and business of anesthesia care. Apollo’s Low Flow Wizard, which has proven to reduce volatile agent costs, provides graphical, actionable insight into fresh gas flow efficiency. Sampled gas can return to the breathing system on workstations to help reduce agent waste and your environmental footprint. And a heated breathing system is designed to prevent condensation build-up, so you can remain focused on your patient, not the technology.

4784

WATCH HOW ONE HOSPITAL REALIZED SIGNIFICANT COST SAVINGS AT WWW.DRAEGER.COM/FLOWLOW

2014-2015

th Corporate

ANNUAL

Profiles

EDWARDS W S LIFESCIENCES SC C S A choice of hemodynamic monitoring options to meet your clinical needs.

dwards Lifesciences’ advanced hemodynamic monitoring and management systems enable individualized hemodynamic optimization. The systems provide clarity into patient status, helping clinicians to make more informed volume management decisions in their moderate- to high-risk surgery patients. Edwards’ extensive line of hemodynamic management sensors, catheters and monitoring tools support clinicians’ needs in the operating room (OR) and ICU. Hemodynamic instability may increase with more complicated or invasive procedures and with the presence of various comorbidities. As a result, clinicians’ hemodynamic monitoring needs and preferences may vary with the complexity of each procedure and patient. Edwards provides a range of monitoring options that can be used in perioperative goal-directed therapy (PGDT) protocols to optimize fluids in moderate- to high-risk surgery patients. Further, the Edwards Enhanced Surgical Recovery program can help implement hemodynamic optimization through PGDT in moderate- to high-risk surgery procedures. The noninvasive ClearSight system extends the clarity of continuous hemodynamic monitoring to moderateand high-risk surgery patients including elderly or obese patients in whom an arterial catheter would not typically be placed – enabling you to make more informed decisions about volume administration in your patients. Parameters monitored include: Stroke Volume (SV), Stroke Volume Variation (SVV), Cardiac Output (CO), Continuous Blood Pressure (cBP). For more information visit, Edwards.com/ClearSight. The minimally invasive FloTrac sensor connects to an existing arterial line to continuously provide dynamic,

flow-based parameters that can be used in PGDT protocols. It is a practical solution for making informed volume management decisions in your moderate- and high-risk surgery patients. The PreSep oximetry catheter continuously measures a patient’s central venous oxygen saturation, providing an earlier and more global view of tissue oxygenation and consumption. The Swan-Ganz pulmonary artery catheter with advanced monitoring capability provides a single, integrated hemodynamic profile for the most complex patients. The Edwards Swan-Ganz catheter remains the leading pulmonary artery catheter for surgical, critical care and trauma patients worldwide. The EV1000 clinical platform presents the physiologic and hemodynamic status of the patient in an intuitive and meaningful way. Designed to work with the FloTrac sensor and PreSep oximetry catheter, the platform offers the scalability and adaptability for both the OR and ICU. Edwards TruWave pressure transducer can be combined with the VAMP (Venous Arterial blood Management Protection) closed-loop blood sampling system to combine accuracy and reliability with the safety of a single closed system, protecting both patients and clinicians from the risk for infection. Edwards offers an extensive line of education and support tools to facilitate the integration of advanced hemodynamic monitoring in acute care settings. Visit www.Edwards.com/CCeducation to review perioperative patient simulations, simulated case studies, product animations and more. Or, visit youtube.com/ECCE4you for OR- and ICU-specific playlists.

AT A GLANCE ADDRESS One Edwards Way Irvine, CA 92614 (800) 424-3278; (949) 250-2500 CriticalCare@Edwards.com www.Edwards.com/CriticalCare Or www.Edwards.com/CCeducation

PRODUCTS Hemodynamic monitoring systems including the ClearSight system; FloTrac sensor; PreSep oximetry catheter; Swan-Ganz pulmonary artery catheter; TruWave pressure transducer; VAMP (Venous Arterial blood Management Protection) system; and EV1000 clinical platform.

With more than 40 years of collaborating with you to advance patient care, Edwards is committed to developing solutions that provide the clarity and control to make more informed decisions. Caution: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Edwards, Edwards Lifesciences, the stylized E logo, Enhanced Surgical Recovery Program, ClearSight, EV1000, FloTrac, PreSep, Swan-Ganz, TruWave and VAMP are trademarks of Edwards Lifesciences Corporation.

The EV1000 clinical platform provides a variety of informative screens from which to choose to provide immediate insight and guide your therapeutic interventions. The platform also allows you to select the parameters most significant for your monitoring requirements, enabling you to make more informed decisions and determine the best course of action.

Anesthesiology News • August 2014

This corporate profile was reviewed and approved by Edwards Lifesciences.

Valuable insight to help you guide volume administration. Clarity gives you the control to make more informed decisions.

ClearSight Noninvasive System CO, SV, SVV, SVR, cBP* FloTrac Minimally-Invasive System CO, SV, SVV, SVR Swan-Ganz System CCO, RVEDV, RVEF, SvO2

Edwards Lifesciencesâ&#x20AC;&#x2122; range of hemodynamic monitoring solutions

The Edwards Enhanced Surgical Recovery Program can help you

provides key flow parameters shown to be more informative in

implement PGDT today. PGDT can help ensure your patients are

determining fluid responsiveness than pressure-based parameters.1

consistently maintained in the optimal volume range.

Each offers continuous information which may be used in

Know more. Know now. <To see how you can individualize therapy under more conditions, download our volume optimization app. URL>

Perioperative Goal-Directed Therapy (PGDT) to hemodynamically optimize your moderate to high-risk surgery patients.

1. Michard F, Biais M. Rational fluid management: dissecting facts from fiction. Br J Anaesth 2012 * Continuous Blood Pressure For professional use. CAUTION: Federal (United States) law restricts this device to sale by or on the order of a physician. See instructions for use for full prescribing information, including indications, contraindications, warnings, precautions and adverse events. Edwards Lifesciences devices placed on the European market, meet the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC, and bear the CE marking of conformity. Edwards, Edwards Lifesciences, the stylized E logo, ClearSight, Enhanced Surgical Recovery Program, FloTrac and Swan-Ganz are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. ÂŠ 2014 Edwards Lifesciences Corporation. All rights reserved. AR11787

Edwards Lifesciences | edwards.com

One Edwards Way | Irvine, California 92614 USA

2014-2015

th Corporate

ANNUAL

Profiles

MAQUET QU MEDICCAL SSYSTEMS S S US USA The Gold Standard

AQUET Medical Systems USA is a market-leading medical device company whose mission is to help improve patient outcomes and quality of life through advanced technology. MAQUET offers comprehensive products and therapeutic solutions for the hybrid operating room (OR), ICU and general OR, as well as for patient transport. MAQUET has a long history of innovation in anesthesia, beginning with the introduction of its first anesthesia machine in 1981. Since then, the company has delivered almost 11,000 units to hospitals worldwide. It also has set market standards with its high-performance SERVO ventilation platform for more than 40 years. The company has a deep understanding of mechanical ventilation and the challenges facing anesthesiologists today. Not only are patient demographics constantly shifting, but surgical procedures are becoming more complex on a daily basis, necessitating advanced technology to ensure optimal patient care. MAQUET invests significantly in research and development to meet the changing needs of hospitals and anesthesiologists, and to ensure that it can provide anesthesia products that offer high-performance ventilation and support capabilities. MAQUET’s flagship anesthesia product, the FLOW-i Anesthesia System® with high-performance SERVO ventilation, offers true ICU ventilator performance and effective anesthesia delivery from the same unit.

AT A GLANCE High-Performance Ventilation Features • Set tidal volume is accurately delivered even under high abdominal and thoracic pressures, helping to avoid hypoventilation. • Fast rise time and high flow rates adapt to varying inspiratory demand in the presence of increasing airway pressure. • Sensitive triggering improves synchrony in pediatric patients and those with decreased respiratory drive. • Consistent and accurate PEEP levels are maintained. • Controlled pressure drop during expiration decreases expiratory resistance and work of breathing, in addition to minimizing auto-PEEP at higher respiratory rates.

Advanced Design and Technology The FLOW-i system’s ergonomically designed, fully electronic platform and touchscreen interface are easy to use and upgrade for enhanced workflow today and in the future. The open architecture allows hospitals to add the patient monitor and data management system of their choice and easily integrate future software and hardware advances into the system—increasing cost efficiency by avoiding the need for costly equipment replacement or upgrades. In addition, clinician ease of use and comfort are engineered into every FLOW-i machine with its height adjustability, movable arms and integrated table light.

U.S. HEADQUARTERS MAQUET Medical Systems USA 45 Barbour Pond Dr. Wayne, NJ 07470 (888) 627-8383 www.maquetusa.com

PRODUCTS Intensive care ventilators and anesthesia machines, suite of cardiovascular products (for intra-aortic balloon counterpulsation, cardiac assist, coronary artery bypass surgery, aortic and peripheral vascular surgery, and extracorporeal circulation), flexible room design for OR and ICU, OR tables, lights and ceiling supply units and OR integration

EMPLOYEES 6,000 MAQUET employees in 50 international sales and service organizations, as well as a network of more than 280 sales representatives

PRESIDENT AND CEO Raoul Quintero

FLOW-i Anesthesia System With High-Performance SERVO Ventilation MAQUET’s FLOW-i Anesthesia System seamlessly combines high-performance SERVO ventilation with precise anesthesia delivery to help meet the needs of all patients. These include the most challenging cases, such as obese patients with high abdominal and thoracic pressures, older patients suffering from multiple medical conditions, the critically ill and the smallest neonates. FLOW-i reacts quickly to changing parameters, as the low internal system volume enables rapid changes in gas concentration when needed, and facilitates fast wash-in and wash-out of the anesthetic agent. This process helps to minimize waste and unnecessary use of the agent through precise delivery technology.

Innovative Volume Reflector™ Re-Breathing Technology The FLOW-i system features the innovative Volume Reflector technology to ensure that the breathing circuit will never be empty and that ventilation will remain uninterrupted regardless of surgical constraints, changing conditions or patient position. The re-breathing technology consists of a rigid reservoir to increase the re-breathing as well as maintain high ventilation performance. It replaces both the traditional bellows and the piston technologies in older systems. Oxygen-driven by design, the Volume Reflector helps to minimize the risk for delivering a potentially dangerous hypoxic mixture in the presence of leaks during low-flow anesthesia. With the new O2Guard, an automatic increase of oxygen will occur if the system detects too-low oxygen at the Y-piece. FLOW-i anesthetic agent injection vaporizers are fully electronic, lightweight and can be refilled while slotted in the machine, even when still in use. The agent delivery is mainly on inspiration, leading to less use of anesthetic agents.

Learn More To learn more about the MAQUET FLOW-i Anesthesia System, visit www.maquetusa.com.

Anesthesiology News • August 2014

This corporate profile was reviewed and approved by MAQUET Medical Systems USA.

2014-2015

th Corporate

ANNUAL

Profiles

MASIMO S O AT A GLANCE Taking noninvasive monitoring to new sites and applications

or 25 years, Masimo has focused on a singular mission—helping clinicians improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications.

Continuing to SET the Benchmark for Oxygenation Monitoring During Challenging Conditions Masimo SET® (Signal Extraction Technology®) is the proven leader in pulse oximetry, demonstrated by both clinical research and the real-world success of customers and OEM partners. More than 100 independent and objective studies have shown that Masimo SET® outperforms all other pulse oximetry technologies, providing clinicians with unmatched sensitivity and specificity to make critical patient care decisions—even under the challenging conditions of motion and low perfusion.1 Most importantly, only Masimo SET® pulse oximetry has been shown to improve patient outcomes by helping clinicians reduce retinopathy of prematurity,2 screen newborns for critical congenital heart disease,3,4 reduce ventilator weaning time5 and save lives, while reducing rapid response activations and ICU transfers on medical-surgical floors.6

rainbow® Technology Helps Clinicians Protect Patients From Hidden Dangers Throughout the Hospital rainbow® technology comprises a suite of continuous, noninvasive measurements designed to help clinicians with some of the most common, costly and critical decisions made in health care today. The rainbow® SET® suite includes: • Total Hemoglobin (SpHb®) • Methemoglobin (SpMet®) • Carboxyhemoglobin (SpCO®) • Oxygen Content (SpOC™) • Acoustic Respiration Rate (RRa®) • All Masimo SET® measurements

® features rainbow® SET® measurements, intuitive touchscreen display, standard wireless radio and full-screen trending.

Anesthesiology News • August 2014

ADDRESS 40 Parker Irvine, CA 92618 (949) 297-7000 www.masimo.com

Helping Clinicians Optimize Blood Management Red blood cell (RBC) transfusion is one of the most frequent procedures performed in U.S. hospitals, with one in 10 inpatients receiving one or more blood units.7 However, a growing body of clinical evidence suggests that overuse of RBC transfusion increases both patient risk and the cost of care.8,9,10,11 Masimo’s continuous, noninvasive total hemoglobin monitoring (SpHb) has been shown to help clinicians reduce RBC transfusions in low blood loss surgery12 and high blood loss surgery.13 In addition, by measuring hemoglobin continuously, SpHb may help clinicians identify real-time drops in hemoglobin that may indicate bleeding. Although SpHb monitoring is not intended to replace blood draws, continuous monitoring of hemoglobin levels could allow earlier interventions that may prevent disability or death.

PRODUCTS Masimo SET® pulse oximetry and sensors; rainbow® Pulse CO-Oximetry and sensors; rainbow Acoustic Monitoring™; SedLine® brain function monitoring; Patient SafetyNet™ remote monitoring and notification system.

MISSION STATEMENT Improving patient outcomes and reducing cost of care by taking noninvasive monitoring to new sites and applications.

Protecting More Patients by Monitoring Every Breath

EMPLOYEES

The Anesthesia Patient Safety Foundation (APSF) and the Joint Commission recommend continuous oxygenation and ventilation monitoring in all patients receiving opioid-based pain medications.14 However, current methods for respiration rate monitoring are limited by accuracy and patient tolerance. Although we offer bestin-class capnography solutions, we believe rainbow Acoustic Monitoring™ with Acoustic Respiration Rate (RRa) can help clinicians better monitor patient breathing in postsurgical and conscious sedation situations due to its demonstrated ability to detect respiratory pause.15

3,500

FOUNDER AND CEO Joe Kiani

The use of the trademarks PATIENT SAFETYNET and PSN is under license from University Health System Consortium.

References 1. Shah N, Ragaswamy HB, Govindugari K, Estanol L. J Clin Anesth. 2012:24:385-391.

Helping Improve Outcomes on MedicalSurgical Units with Masimo Patient SafetyNet™a

2. Castillo A, et al. Acta Paediatr. 2011;100:188-192.

In August 2012, the Joint Commission Sentinel Event Alert on the safe use of opioids in hospitals recommended implementation of better dosing along with continuous oxygenation and ventilation monitoring (instead of spot-checks) in postsurgical patients.16 Our Patient SafetyNet system combines Masimo SET® pulse oximetry, breakthrough rainbow® measurements and remote patient monitoring with wireless clinician alerts. After implementing Masimo SET® and Patient SafetyNet on a postsurgical floor where only intermittent spot-checking was used before, Dartmouth-Hitchcock Medical Center reduced rapid response activations by 65% and ICU transfers by 48%,6 and saved $1.48 million annually. In addition, no patients suffered irreversible, severe brain damage or died as a result of respiratory depression from opioids over a five-year period.17

5. Durbin CG Jr, et al. Crit Care Med. 2002;30:1735-1740.

3. de-Wahl Granelli AD, et al. BMJ. 2009;338. 4. Ewer A, et al. Health Technol Assess. 2012;16:1-184.

6. Taenzer AH, et al. Anesthesiology. 2010;112:282-287. 7. AHRQ. Inpatient Sample. 1997-2007. 8. Marik PE, et al. Crit Care Med. 2008;36:2667-2674. 9. Carson JL, et al. Cochrane Database Syst Rev. 2012;4:CD002042. 10. Shander A, et al. Transfusion. 2010;50:753-765. 11. Murphy GJ, et al. Circulation. 2007;116:2544-2552. 12. Ehrenfeld JM, et al. American Society of Anesthesiologists Annual Meeting. 2010:LB05 (abstract). 13. Awada WFN, Maher F. Proceeding of the Society for Technology in Anesthesia Annual Meeting. 2013:51. 14. Stoelting RK, et al. APSF Newsletter. 2011. www.apsf.org. 15. Ramsay M, et al. Anesth Analg. doi: 10.1213/ ANE.0b013e318290c798. 16. The Joint Commission. Sentinel Event Alert! 2012:49. 17. Taenzer AH, et al. APSF Newsletter. 2012;27:1.

This corporate profile was reviewed and approved by Masimo.

New from Masimo

ISA connects to Root via Masimo Open Connect™ (MOC-9™)

™

Nomoline™ (No Moisture sampling line) Reduces disposable costs through extended monitoring and use of non-proprietary cannulas

2014-2015

th Corporate

ANNUAL

Profiles

MINDRAY “healthcare within reach”

s a leading developer, manufacturer and marketer of anesthesia and life support systems, patient monitors, in vitro diagnostics and medical imaging products, Mindray is dedicated to delivering the highest quality medical instrumentation to a global market. Founded in 1991 and headquartered in Shenzhen, China, Mindray is the third largest manufacturer of anesthesia systems and patient monitors worldwide. In 2008, Mindray acquired Datascope’s patient monitor business, which has been a leader in patient monitoring products since it was founded in 1964. With more than 8,000 employees and R&D centers on three continents, Mindray offers a broad range of innovative solutions designed to contain costs while ensuring the highest quality products for patient care. Today, Mindray’s products and services can be found in health care facilities in more than 190 countries. Inspired by the needs of our customers, we adopt advanced technologies and transform them into accessible innovation, bringing healthcare within reach. Our outstanding sales professionals and clinical education specialists provide your staff with comprehensive, on-site training and in-service. Our dedicated field service and in-house technical support organization is one of the largest direct service teams in the industry. Learn how we can help you maximize your resources with some of the most advanced and accessible medical equipment in the industry.

The A3 Anesthesia System provides many of the features and benefits of an advanced anesthesia delivery system for the outpatient and mid-acuity environment. The A-Series has an industry-leading two-hour backup battery supply and is capable of delivering fresh gas and anesthetic agent in the event of total loss of power.

Anesthesia Delivery Systems

Powerful Technology in Patient Monitoring and Network Solutions

The A-Series platform combines the simplicity of traditional anesthesia delivery with advanced features and evolving technology. The A5’s award-winning design, intuitive user interface and advanced ICU quality ventilation modes support effective care across a wide range of patients. The 15-inch color touchscreen is ergonomically designed for comfortable interaction and visibility, allowing clinicians to easily select ventilation modes and adjust settings. Automatic compliance and fresh gas compensation maintain accurate tidal volumes. The temperature-controlled breathing system is maintained at body temperature and virtually eliminates internal condensation. The A5 Anesthesia System comes standard with comprehensive ventilation modes: volume control ventilation, pressure-controlled ventilation with or without volume guarantee, pressure support and synchronized intermittent mandatory ventilation with either volume or pressure control support. Spirometry, high-pressure O2 port, central locking brake, mounting rails, adjustable workspace lighting and an innovative backup control touch pad also come standard. Optional integrated gas analysis with dual-agent auto-ID, aged-based MAC values and capnography further enhance the A5’s ability to support high-acuity requirements. Safety features include a unique auxiliary oxygen and air-flow meter that delivers blended gas through the nasal cannula, decreasing the potential risk for surgical fire.

AT A GLANCE

Anesthesiology News • August 2014

Anesthesia Connectivity Connectivity or interoperability is at the core of the A-Series Anesthesia System platform. Since the government stimulus programs of ARRA and HITECH passed in 2009, the health care industry has seen the adoption of electronic health record (EHR) and anesthesia information management systems in record numbers. To this point, Mindray has been a leader, developing integrated solutions for seamless data exchange. Serial communication, Ethernet communication or both can be deployed using industry standard HL7 protocols. Through this integration, the A-Series Anesthesia Systems are well equipped to meet the interoperability requirements for integration engines and EHR systems.

Anesthesia Consumables Mindray is now a one-source provider of anesthesia equipment and consumable products, offering a competitive line of quality breathing circuits, anesthesia circuit kits, breathing masks, laryngeal airway masks, filters and gas monitoring accessories.

The DPM6 and DPM7 offer a broad range of patient monitoring capabilities in a rugged, modular design. The DPM7’s large 17-inch touchscreen display is most appealing in the operating room, where visibility and convenience are essential. The DPM6’s flexibility and modularity combine with its 12-inch touchscreen display and matching user interface to offer a complementary monitoring solution for postoperative areas. Supporting up to eight invasive pressures and features such as auto-ID of anesthetic agents, carbon dioxide, nitrous oxide and oxygen, combined with monitored anesthesia care and BIS monitoring, the DPM6 and

NORTH AMERICAN HEADQUARTERS Mindray North America 800 MacArthur Blvd. Mahwah, NJ 07430

MINDRAY GLOBAL HEADQUARTERS Keji 12th Road South High-Tech Industrial Park Nanshan, Shenzhen 518057 P.R. China

PRODUCTS AVAILABLE IN THE UNITED STATES Anesthesia delivery systems, breathing circuits, laryngeal airway masks, ultrasound imaging, full line of patient monitors, central stations, telemetry and networking solutions.

EMPLOYEES 8,000 worldwide

PRESIDENT MINDRAY NORTH AMERICA George Solomon

DPM7 represent a powerful combination of advanced functionality and extraordinary value. The newly introduced T1 Compact Transport Monitor offers a brilliant 5-inch touchscreen display and robust monitoring capabilities—all in a versatile 2-lb package.

Ultrasound Imaging Tools Mindray’s M-Series ultrasound systems are practical and effective procedural tools for anesthesia professionals. They enable visualization of target structures before and during anesthesia procedures. The M5 and M7 ultrasound systems are uniquely designed for the procedural room environment. Notable attributes include compact and durable design, a sealed surface for easy cleaning and infection control, exceptional image quality and simple and intuitive operation. The M-Series offers iNeedle needle visualization software, customizable reports and a complete on-board solution for patient information management and connectivity. Users also can select from a wide range of specialty transducers and optional features to meet clinical needs.

Learn More To learn more about how Mindray can help you realize more value in your anesthesia solutions, contact your local sales specialist at (800) 288-2121, or visit us at www.mindray.com.

This corporate profile was reviewed and approved by Mindray.

itâ&#x20AC;&#x2122;s your world Mindray provides a broad range of solutions across the peri-operative environment to support you in the care of your patients. From advanced A-Series anesthesia delivery systems, a new line of single-use breathing circuits and kits, and versatile patient monitors, to flexible transport solutions and portable ultrasound systems â&#x20AC;&#x201C; Mindray offers a world of quality, easy to use, innovative, yet affordable solutions that help simplify the challenges of your complex world.

Mindray North America, 800 MacArthur Blvd., Mahwah, NJ 07430 800.288.2121 www.mindray.com

2014-2015

th Corporate

ANNUAL

Profiles

PACIRA PHARMACEUTICALS, INC.

acira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products to address the needs of acute care practitioners and their patients. Pacira is driven by a dynamic workforce committed to optimizing patient care and satisfaction in the acute care setting, with a special focus on improving outcomes in postsurgical pain management.

A Proprietary Drug Delivery Platform The cornerstone of the Pacira product portfolio is DepoFoam®, a proprietary drug delivery platform designed to extend a medication’s duration of action without altering its molecular structure. The DepoFoam carrier matrix is made up of multivesicular liposomes that encapsulate a drug. Each chamber is separated by lipid membranes that naturally erode to release the drug over a desired period of time.

case for EXPAREL as the foundation of an opioid-sparing multimodal postsurgical pain management regimen. Recently published national and regional retrospective analyses2,3 of more than 350,000 postsurgical patients receiving opioids concluded that those who experienced opioid-related adverse events had both longer hospital lengths of stay and higher hospitalization costs. The company’s efforts are buoyed by a groundswell movement led by government and independent health care organizations to mitigate potentially fatal side effects related to opioid use by recommending a shift toward opioid-sparing pain regimens, especially in highrisk postsurgical patients.

Clinical Utility Across a Broad Range Of Potential Applications EXPAREL has broad applications across multiple surgical specialties, as well as in the anesthesiology arena, including use as an infiltration into the transversus abdominis plane for postsurgical analgesia following abdominal procedures. In May, Pacira submitted a Supplemental New Drug Application to the FDA for a nerve block indication for EXPAREL based on positive data from a Phase III study assessing the safety and efficacy of EXPAREL in femoral nerve block for total knee arthroplasty.

The Pacira Advantage

A First of Its Kind, Single-Dose Local Analgesic In 2012, Pacira successfully launched EXPAREL® (bupivacaine liposome injectable suspension), the first and only DepoFoam-based local analgesic. Indicated for administration into the surgical site to produce postsurgical analgesia, a single dose of EXPAREL provides nonopioid pain control with reduced opioid requirements for up to 72 hours* without the need for catheters or pumps.1

Shifting the Postsurgical Pain Management Paradigm The launch of EXPAREL is bolstered by a robust Phase IV clinical program, which builds a compelling

Anesthesiology News • August 2014

Discovery, innovation and proprietary expertise are the hallmarks of the Pacira competitive advantage. The company not only holds the exclusive rights and expertise to DepoFoam, but owns the unique distinction of being the only company in the world with the ability to manufacture DepoFoam-based products, such as EXPAREL, on a large commercial scale. With steadily increasing demand and a growing list of potential clinical applications, Pacira and EXPAREL are poised to become vital fixtures in the postsurgical pain management arena. For more information about Pacira Pharmaceuticals Inc., visit www.pacira.com. *Pivotal studies have demonstrated the safety and efficacy of EXPAREL in patients undergoing hemorrhoidectomy and bunionectomy procedures.

AT A GLANCE ADDRESS 5 Sylvan Way Parsippany, NJ 07054 (973) 254-3560 www.Pacira.com For more information on EXPAREL, visit www.EXPAREL.com For medical inquiries related to EXPAREL, contact Medical Information at medinfo@pacira.com or 1-855-RX-EXPAREL (1-855-793-9727)

Important Safety Information For EXPAREL EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use in patients younger than 18 years of age. Non–bupivacainebased local anesthetics, including lidocaine, may cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations of bupivacaine should not be administered within 96 hours after administration of EXPAREL. Monitoring of cardiovascular and neurological status as well as vital signs should be performed during and after injection of EXPAREL, as with other local anesthetic products. Because amidetype local anesthetics, such as bupivacaine, are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk for developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence ≥10%) following EXPAREL administration were nausea, constipation, and vomiting. 1. Gorfine SR, et al. Diseases of the Colon & Rectum. 2011;54(12):1552-1559. 2. Oderda GM, et al. Journal of Pain & Palliative Care Pharmacotherapy. 2013;27(1):62-70. 3. Kessler ER, et al. Pharmacotherapy. 2013;33(4):383-391. PP-EX-US-0185

This corporate profile was reviewed and approved by Pacira Pharmaceuticals, Inc.

2014-2015

th Corporate

ANNUAL

Profiles

TELEFLEX

eleflex believes in improving the health and quality of people’s lives. We apply purpose-driven innovation—a relentless pursuit of identifying unmet clinical needs—in a way that benefits patients, providers and society. We offer practical solutions that build, nurture and strengthen the vital parts at the heart of health care. Our ARROW®, Hudson RCI®, LMA® and Rusch® brands shape our portfolio of proven medical products and technologies. These distinguished brands are united by their common sense of purpose in providing anesthesia and respiratory therapy solutions.

LMA Airway Management™ LMA Better by Design® The LMA Airway Management family of products from Teleflex has a proven track record of safety and efficacy, building on a 20-year history of innovation and trust. Each LMA® airway has been carefully designed and tested to meet exacting standards. LMA airways are included in the American Heart Association Guidelines for Resuscitation and the American Society of Anesthesiologists Difficult Airway Algorithm. The LMA Supreme® Single-Use Airway from Teleflex combines the best features of all previous LMA airways and is designed for safety and ease of use. Whether it’s for a routine procedure or to manage a higher-risk patient, the LMA Supreme Airway’s higher seal pressure and gastric access deliver a higher degree of safety. It provides gastric access to suction or to decompress the stomach if the physician so chooses, and is designed to channel fluids away from the airway in the unlikely event of active or passive regurgitation, while also allowing for diagnostic testing and verifiable positioning.

The Next Generation in One-Lung Ventilation

The Rusch® EZ-Blocker™ endobronchial blocker from Teleflex offers an intuitive, secure solution for clinicians to achieve one-lung ventilation and reduce intraoperative malpositioning. It was designed by anesthesiologists who challenged accepted clinical practices and wanted a better way to treat patients. The unique bifurcated distal end of the Rusch EZ-Blocker endobronchial blocker allows for the intuitive placement of the cuffs in the right and left bronchi. Once the Rusch EZ-Blocker endobronchial blocker is advanced through the distal end of a single-lumen endotracheal tube, the

bifurcated cuffs separate and are naturally directed into the left and right mainstem bronchi. The Rusch EZ-Blocker endobronchial blocker securely saddles the carina. The securement cap allows the catheter to be tightened once properly positioned, which minimizes the need to manipulate it after placement and reduces the potential for the cuffs to become dislodged.

Needle-Free Solutions for Drug Delivery The LMA Atomization® family of products from Teleflex provides a simple-to-use, needle-free solution for use with drugs approved for intranasal and oropharyngeal delivery. The LMA ® MAD Nasal™ intranasal mucosal atomization device is the safe, painless and rapidly effective treatment that offers quick absorption across mucosal membranes to the bloodstream. The LMA® MADgic Airway™ intubating airway with mucosal atomization and oxygen delivery is the most innovative choice to create a temporary airway to facilitate fiber-optic intubation, combining atomized topical anesthetic and oxygen delivery in an innovative and elegantly designed oral airway. The LMA® MADgic® laryngo-tracheal mucosal atomization device is the most versatile choice to administer medication across the entire upper airway and beyond the vocal cords.

Post-Op Pain Management Solutions The ARROW® FlexBlock® echogenic continuous peripheral nerve block (CPNB) catheter and the ARROW® AutoFuser® disposable pain pump from Teleflex allow clinicians to combine efficient and accurate catheter placement with a reliable, unimpeded infusion of medication. The ARROW FlexBlock CPNB catheter is an echogenic, flexible, kink-resistant catheter designed to help clinicians better control patient pain and improve overall block success. The ARROW AutoFuser disposable pain pump delivers medication safely and reliably, helping to improve patient quality of life following a procedure. The ARROW AutoFuser disposable pain pump offers the right pain pump to meet a variety of clinical demands, allowing clinicians to provide individualized patient pain control and adjust therapy as needed.

Reducing Cross-Contamination, Reducing Cost The risk for cross-contamination during intubation of the trachea exists because no perfect procedure for decontamination exists. 1 Single-use devices offer the opportunity to reduce potential for infection associated with reusable devices.

This corporate profile was reviewed and approved by Teleflex.

AT A GLANCE ADDRESS 550 E. Swedesford Rd., Suite 400 Wayne, PA 19087

PRODUCTS LMA® Airways, Rusch® EZ-Blocker™ Endobronchial Blocker, Rusch® ET Tubes and Laryngoscopes, ISO-Gard® Mask with ClearAir™ Technology, ARROW® Pain Management

EMPLOYEES 11,400

CHIEF EXECUTIVE OFFICER Benson Smith

Green Rusch® Lite™ and Rusch® EquipLite™ disposable metal laryngoscope blades are single-use blades that offer users the performance and feel of a reusable metal blade. These blades eliminate the hassles associated with reusable blades, including the time and cost of reprocessing, without sacrificing strength or light quality.

Limiting Waste Anesthetic Gas Exposure In the PACU An invisible risk exists in the postanesthesia care unit (PACU). Patients are exhaling waste anesthetic gas (WAG) into the breathing zone of their attending nurses,2 and although it cannot be detected by sight or odor, PACU clinicians can take action to protect themselves from the potential health effects. The first of its kind, the ISO-Gard® mask with ClearAir™ technology from Teleflex was developed in partnership with clinicians who identified the issue and wanted to take action. As the only solution available for “source control” of waste gases, the specialized ClearAir technology of the ISO-Gard mask simultaneously delivers oxygen to patients and scavenges their exhalation to help limit exposure faced by clinicians and minimizes the cumulative effect of low-level exposure to WAG.

References 1. Disposable laryngoscope blades do not interfere with ease of intubation in scheduled general anesthesia patients. Eur J Anaesthesiol. 2003;20:731-735. 2. Occupational Safety and Health Administration, U.S. Department of Labor. Anesthetic gases: guidelines for workplace exposures. Revised May 18, 2000. http://www.osha.gov/dts/osta/anestheticgases. EquipLite is a trademark of Truphatek International Ltd. AutoFuser is a registered trademark of Ace Medical Co., Ltd. Teleflex, ARROW, ClearAir, EZ-Blocker, FlexBlock, Green Rusch Lite, Hudson RCI, ISO-Gard, LMA, LMA Airway Management, LMA Atomization, LMA Better by Design, LMA Supreme, MAD, MAD Nasal, MADgic, MADgic Airway and Rusch are trademarks or registered trademarks of Teleflex Incorporated or its affiliates.

Anesthesiology News • August 2014

3333

2014-2015

th Corporate

ANNUAL

Profiles

PAR STERILE S PRODUCTS, O UC S, LLCC “Providing patients and customers with uncompromising quality and value.” Quality You Can Depend On

The legacy of Par Sterile Products reaches back to the birth of the American pharmaceutical industry at the turn of the 20th century. With a sterile manufacturing facility located in Rochester, Mich., Par Sterile Products possesses an unparalleled reputation for high-quality products and an impeccable record of regulatory compliance. Our iconic brands, such as Aplisol® and Adrenalin®, have been relied on by physicians and patients for decades. While proud of our heritage, we are even prouder of the great things we are accomplishing today. In an injectables world frequently plagued by compliance issues and product shortages, Par Sterile Products stands as a highly regarded partner with exemplary trade service levels and an impeccable record of regulatory compliance. Every week in America, more than 1 million Par prescriptions are dispensed, including Par Sterile Products. In return for the trust that is placed in us, we are committed to providing products of uncompromising quality. In fulfilling this mission, we deliver value to our customers and the physicians and patients who rely on us.

Partners for Health Care Excellence Par Sterile Products, LLC, a subsidiary of Par Pharmaceutical, Inc., is at the forefront of developing, manufacturing, marketing and distributing safe, innovative and cost-effective branded and generic aseptic injectable pharmaceuticals that help improve patient quality

Anesthesiology News • August 2014

of life. We also provide contract manufacturing services to our partners in the biopharmaceutical and pharmaceutical industry. Today, our company’s sales, together with Par Pharmaceutical, Inc., and its other subsidiaries, place it among the top five largest generic pharmaceutical companies in the United States. At Par Sterile Products, our most important resource is the talent and dedication of our nearly 500 employees, each of whom is part of a culture that values integrity, customer focus, teamwork and performance.

AT A GLANCE ADDRESS Morris Corporate Center 2 One Upper Pond Rd., Building D, 3rd Floor Parsippany, NJ 07054

CUSTOMER SERVICE (877) 547-4547

DRUG SAFETY/MEDICAL INFORMATION (800) 828-9393 Option 3

CHIEF EXECUTIVE OFFICER Paul Campanelli

Promising Product Pipeline Par Sterile Products currently markets a portfolio of 14 specialty injectable products, including Brevital®, Dantrium®, Pitocin® and zoledronic acid. Since 2012, Par Sterile Products has launched nine new products. We possess one of the most promising new product pipelines in the injectable space, having developed a pipeline currently consisting of 34 products, 17 of which have already been submitted for FDA approval. We expect at least a half-dozen more ANDA filings before year end, fueled by our commitment to investment in research and development. At Par Sterile Products, we are large enough to maintain a significant trade presence, yet agile enough to provide maximum attention to our customers, and we remain poised to continue our impressive track record of success. For more information, please visit www.parpharm.com.

PAR—People Achieving Results!

This corporate profile was reviewed and approved by Par Sterile Products, LLC.

Par Sterile Products, LLC O u r R a p i d y G row i n g P ro d u c t L i n e I n c l u de s

Dantrium IV ÂŽ

(dantrolene sodium for injection)

Easy to open, easy to use t &BTZ UP PQFO Ă¸JQ PĂ˛ WJBM DBQ t &BTZ UP JEFOUJGZ 3&% WJBM DBQ BOE 3&% WJBM MBCFM Shelf life t DantriumÂŽ IV IBT NPOUIT PG TIFMG MJGF t 5IF MPOHFS TIFMG MJGF PG DantriumÂŽ IV USBOTMBUFT UP DPTU TBWJOHT XIFO QSJDFE UIF TBNF BT UIF HFOFSJD Emergency orders *G ZPV NVTU IBWF DantriumÂŽ IV EFMJWFSFE RVJDLMZ DBMM UIF 1BS 4UFSJMF 1SPEVDUT --$ DantriumÂŽ IV &NFSHFODZ 0SEFST BU BOE TFMFDU PQUJPO To order DantriumÂŽ IV EBOUSPMFOF TPEJVN GPS JOKFDUJPO Lyophilized Powder EJSFDUMZ GSPN 1BS 4UFSJMF 1SPEVDUT --$ DBMM PS GBY DantriumÂŽ IV JT BMTP BWBJMBCMF UISPVHI ZPVS MPDBM XIPMFTBMFST BOE EJTUSJCVUPST

NDC 42023-123-06

Name DantriumÂŽ IV (dantrolene sodium for injection)

Strength 20 mg

Vial Size 70 mL SDV

Unit of Sales 6

For more information on DantriumÂŽ IV and for Full Prescribing Information please visit www.dantrium.com. DantriumÂŽ is a registered trademark of Par Sterile Products, LLC.

PSPB00 0028

2014-2015

th Corporate

ANNUAL

Profiles

SSPACELABS C S HEALTHCARE C

pacelabs Healthcare is a comprehensive, perioperative solutions provider developing, manufacturing and distributing medical equipment and services throughout the world. We provide solutions for patient monitoring and connectivity, anesthesia delivery and ventilation, diagnostic cardiology and supplies and accessories, selling to hospitals, clinics and physician offices. Spacelabs’ world headquarters, in Snoqualmie, Wash., is where we develop and manufacture anesthesia, patient monitoring and cardiology products. Spacelabs provides various perioperative solutions from low to high acuity, covering simple to complex cases and pediatric to geriatric patients—offering you the choices you need in anesthesia delivery, patient monitoring and supplies and accessories. What’s more, you can configure solutions to satisfy your individual practices and preferences. Our product line is continually developing and expanding with some exciting new additions coming in the near future. Spacelabs Healthcare has more than 50 years of innovation and service and began as the innovator of life support systems for the Gemini and Apollo space missions. Always endeavoring to meet our customers’ unmet needs, the result is the complete rethinking of the anesthesia delivery system experience.

Welcome to ARKON Until today, anesthesia delivery systems were designed with functionality and reliability as the priority. While important, we saw these as our starting point. ARKON™ is our “evolutionary” new anesthesia delivery system that pushes the boundaries to provide advanced flexibility and ergonomics for you, the people who use these machines. ARKON puts your patient front and center—offering anesthesiologists the maximum in functionality, comfort and control. Through a combination of an expandable clinical console, which extends out to enable a wide-angle view of your clinical setting, and enhancements not previously available in the perioperative environment, we focused ARKON on you, so you can focus on your patient. While other machines concentrate on the technology of anesthesia delivery, we believe you will find ARKON unique in its attention to the details of how you work. Providing you with an improved workplace is our priority, with flexibility our focus. Designed to improve the user experience, ARKON is part of our mission to inspire the world to bring the best care to patients as well as their families.

Spacelabs Healthcare is dedicated to developing and supporting those tools.

Spacelabs Healthcare Collaborates With Clinicians To Provide Clinically Relevant Products Spacelabs Healthcare values the strong clinical partnerships that we have developed and maintained over the past half-century. Through continuous and effective communication with clinical user groups, we gather a deep understanding of needs and requirements in order to develop solutions to help clinicians achieve their goals. Always a leader in innovation with accessibility, continuity and partnership, Spacelabs Healthcare delivers on our promises to: • Help improve patient care. • Help clinicians achieve their goals. • Demonstrate honesty, reliability and integrity. • Deliver quality products and service, service, service.

Excellence in Customer Service and Support

AT A GLANCE ADDRESS 35301 SE Center St. Snoqualmie, WA 98065 (425) 396-3300 www.spacelabshealthcare.com marketing@spacelabs.com

PRESIDENT AND CEO Nicholas Ong

When selecting a perioperative solutions company, consider Spacelabs’ experience and heritage of innovative and intuitive products developed in partnership with our customers to address real-life clinical needs. Our customer-first philosophy reflects our commitment to superior care for you and your patients as well as product support by our award-winning service team.

At Spacelabs Healthcare, excellence in customer service and support are not just words; they are values, embraced by all our employees, that shape the way that we do business. As a result, IMV ServiceTrak™, one of the most respected surveys in the health care industry, ranked Spacelabs “Best for Overall Service Performance among Industry Peers” in 2011 for the second consecutive year, and three of the last six years. We work cooperatively to develop long-term relationships with our suppliers, our distribution partners and our customers to provide the products, tools and services you need. Spacelabs is a focused, agile organization that is here to serve health care professionals worldwide. Our goal is to provide our customers more time to care. Customer loyalty is our reward.

“The Spacelabs Advantage” For more than 50 years, health care professionals have experienced the company’s proven commitment to connecting innovation with care; stability for a strong future; collaboration with clinical and technological partners; effective implementation of real-world solutions; and service wherever, whenever and however it’s needed. The most important factor in patient care is a knowledgeable medical professional with the right tools.

Anesthesiology News • August 2014

This corporate profile was reviewed and approved by Spacelabs Healthcare.

Because You and Your Patients are Worth It. Welcome to ARKON™, our “evolutionary” new anesthesia delivery system that features an expandable clinical console which extends out to enable a wide-angle view of the clinical setting. Get closer to your patients. Get a closer look. Request a demonstration today.

*()+ KhY[]dYZk @]Ydl`[Yj] Kh][aÚ[Ylagfk kmZb][l lg [`Yf_] oal`gml fgla[]&

2014-2015

th Corporate

ANNUAL

Profiles

TEAMHEALTH ANESTHESIA S S

eamHealth Anesthesia is a nationally recognized provider of comprehensive anesthesia services. Our proven service platform is specifically designed to optimize quality of care; patient and surgeon satisfaction; and operational efficiency. TeamHealth’s 35 years of success in providing local physician partners is built on supporting our providers so they can concentrate on taking care of every patient they see and supporting success in each department we serve. TeamHealth providers care for more than 12 million patients per year, giving us the expertise to hardwire both clinical and operational best practices. With extensive experience as anesthesia providers, business managers and hospital/medical staff leaders, the TeamHealth Anesthesia leadership team is unsurpassed in helping improve the performance of their anesthesia departments. Whether augmenting an existing anesthesia group or forming a new one, TeamHealth Anesthesia provides customized solutions and first-rate specialists. In fact, we are anesthesia industry leaders in: • Surgeon satisfaction • Quality and metric performance, measurement and reporting • Patient safety • Recruitment and retention of anesthesiologists and certified registered nurse anesthetists (CRNAs) • Operating room (OR) efficiency • Group management and leadership • Billing, collections and credentialing

Your Career Will Thrive With TeamHealth Anesthesia Founded by anesthesiologists, TeamHealth Anesthesia uniquely understands the needs and expectations of anesthesiologists and CRNAs. Our solid reputation in the provider community allows us to partner with the best anesthesia clinicians in the market, creating stable, top-notch groups for our hospital and surgeon partners. To continue our success, we need leading clinicians like you to be part of our team.

Anesthesiology News • August 2014

ADDRESS 7111 Fairway Dr., Ste. 450 Palm Beach Gardens, FL 33418 (877) 799-3552 anesthesiajobs@teamhealth.com www.teamhealth.com

• Nurture your professional interests while advancing your career • Receive a highly competitive salary with benefits and performance incentives • Choose from coast-to-coast nationwide practice opportunities • Practice medicine without the daily burdens of managing a practice • Focus on what matters most to you—patient care

SERVICES TeamHealth Anesthesia is one of the nation’s leading outsourced anesthesia and pain management service organizations—specializing in delivering high-quality, cost-effective and servicefocused patient care.

Best of all, when you’re part of our “team,” we’ll provide unparalleled resources that will help you be one of the best anesthesia professionals in the nation. Through timely risk management and our leadership skills education programs like LEAD™, the TeamHealth Leadership Development Institute™ and others, you’ll discover that we care as much about your career and quality of life as you do.

•

Anesthesia Care Team

•

Anesthesia programs nationwide are moving from the physician-only anesthesia service delivery models to mixed-care team models with both physicians and CRNAs. TeamHealth Anesthesia has extensive experience in the anesthesia care team (ACT) model and has successfully transitioned numerous physician-only models to ACT models. Our experience has shown us that the benefits of the ACT model include improved practice efficiencies, increased revenue and profits, standardization of care, flexibility and increased patient and surgeon satisfaction. Always sensitive to the needs of surgeons and the hospitals we serve, TeamHealth Anesthesia implements the following transition activities with minimal disruption to the existing anesthesia program:

Coast-to-Coast Opportunities Your perfect practice is waiting for you at TeamHealth Anesthesia. We have practices throughout the United States, so whether you’re looking for cities, suburbs, mountains or beaches, we have the practice you want, where you want, just waiting for you to make

AT A GLANCE

it your own. Our partner hospitals range from community hospitals in comfortable bedroom townships to major medical centers and teaching facilities in urban areas. With a wide variety of practice environments and case mixes as well as varying anesthesia delivery models—from direct anesthesia care to anesthesia care teams—you’ll find opportunities to:

• Recruit anesthesia medical directors who possess a strong customer service mindset, support their respective hospital’s vision and goals, communicate with surgeons to ensure mutual understanding of the ACT model to be implemented, have experience

•

• •

working with CRNAs and create positive group cultures. Recruit and retain a core group of physicians and CRNAs. Provide team-building workshops with anesthesia providers, surgical leadership and the hospital executive team. Appoint an internal chief CRNA to help physicians and CRNAs work as a team. Leverage TeamHealth’s national customer service training programs to improve satisfaction scores. Implement daily anesthesia “team huddles” to ensure all processes are properly in place for surgeries and patients scheduled for the next day.

By implementing the ACT model, our client hospitals see faster room turnovers as well as drastically improved efficiency and reduced costs.

The Right Job. The Right Place. The Right Partner. TeamHealth Anesthesia is one of the nation’s leading outsourced anesthesia organizations. Specializing in delivering high-quality, cost-effective and servicefocused patient care, our services maximize OR performance while increasing patient and surgeon satisfaction. For more information, visit us online at www. teamhealth.com, call (877) 799-3552, or email anesthesiajobs@teamhealth.com.

This corporate profile was reviewed and approved by TeamHealth Anesthesia.

“We wanted clinical autonomy, ﬁnancial reward, and a partner with experience and size. TeamHealth gave us the whole package.”

~Alan Gwertzman, M.D. Teaneck, NJ

Is it time to consider a sale or merger? Rich Berube 865.293.5638 or Janette Stephenson 954.377.2924 rich_berube@teamhealth.com

janette_stephenson@teamhealth.com

TeamHealth Anesthesia is the premier partner for anesthesia groups. It is part of TeamHealth, one of the largest providers of outsourced physician services offering integrated clinical solutions to hospitals in the areas of emergency medicine, hospital medicine, specialty hospitalists, anesthesia, urgent care and pediatrics. teamhealthanesthesia.com

2014-2015

th Corporate

ANNUAL

Profiles

MCMAHON PUBLISHING

cMahon Publishing was founded in 1972 by Raymond E. McMahon and has grown to become one of the nation’s largest family-owned medical publishers. McMahon publishes a broad array of medical newsmagazines in various specialties, including anesthesiology, gastroenterology, general surgery, hospital and specialty pharmacy, infectious diseases, pain medicine and oncology. The combined circulation of McMahon publications is approximately 300,000 doctors and pharmacists. Foremost among McMahon publications is Anesthesiology News. Now in its 40th year, Anesthesiology News has been the best-read publication for the specialty for the past 17 years (according to Kantar Media). Nearly 93% of the 47,524 U.S.-based anesthesiologists read this publication each month. McMahon newsmagazines are accompanied by a full line of digital media, including websites, mobile sites, iPad apps, e-newsletters, digital editions, multimedia, social media and other digital communications.

AT A GLANCE

McMahon publishes: •

ADDRESS

Anesthesiology News • Anesthesiology News Buyer’s Guide • Anesthesiology News Guide to Airway Management • Anesthesiology News Special Edition

545 W. 45th St., 8th Floor New York, NY 10036 (212) 957-5300 www.mcmahonmed.com www.anesthesiologynews.com @anesthesianews

•

Clinical Oncology News

•

Gastroenterology & Endscoscopy News

•

General Surgery News

•

Infectious Disease Special Edition

•

Pain Medicine News

•

Pharmacy Practice News

•

Specialty Pharmacy Continuum

anesthesiologynews

PRODUCTS Medical newsmagazines, custom medical publications, educational reviews, special editions, podcasts, pocket guides and more.

EMPLOYEES 60

PUBLISHER AND MANAGING PARTNER Raymond E. McMahon

GENERAL MANAGER, PARTNER Matthew McMahon

ANESTHESIOLOGY NEWS Editorial Director James Prudden Senior Group Publication Director Richard Tuorto Manager, Publication Sales Angela Labrozzi Production Manager Martin Barbieri Art Director Blake Dennis

BUYER’S GUIDE

Anesthesiology News • August 2014

SPECIAL EDITION

This corporate profile was reviewed and approved by McMahon Publishing.